CuraGen, Alexion Ink Drug-Target, Validation Alliance | GenomeWeb

NEW YORK, March 12 - CuraGen and Alexion Pharmaceuticals on Tuesday said they have signed a deal to discover and validate cancer-related biologic and small-molecule drug targets.

Terms of the multi-year agreement, which may grow in the future to include other diseases, call for CuraGen to apply its functional genomic technologies to help Alexion identify drug targets from data the biotech company will provide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.